Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation

Veronika Bachanova, Daniel J. Weisdorf, Tao Wang, Steven G E Marsh, Elizabeth Trachtenberg, Michael D. Haagenson, Stephen R. Spellman, Martha Ladner, Lisbeth A. Guethlein, Peter Parham, Jeffrey S. Miller, Sarah A. Cooley

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Donor killer immunoglobulin-like receptor (KIR) genotypes are associated with relapse protection and survival after allotransplantation for acute myelogenous leukemia. We examined the possibility of a similar effect in a cohort of 614 non-Hodgkin lymphoma (NHL) patients receiving unrelated donor (URD) T cell–replete marrow or peripheral blood grafts. Sixty-four percent (n = 396) of donor-recipient pairs were 10/10 allele HLA matched and 26% were 9/10 allele matched. Seventy percent of donors had KIR B/x genotype; the others had KIR A/A genotype. NHL patients receiving 10/10 HLA–matched URD grafts with KIR B/x donors experienced significantly lower relapse at 5 years (26%; 95% confidence interval [CI], 21% to 32% versus 37%; 95% CI, 27% to 46%; P =.05) compared with KIR A/A donors, resulting in improved 5-year progression-free survival (PFS) (35%; 95% CI, 26% to 44% versus 22%; 95% CI, 11% to 35%; P =.007). In multivariate analysis, use of KIR B/x donors was associated with significantly reduced relapse risk (relative risk [RR],.63, P =.02) and improved PFS (RR,.71, P =.008). The relapse protection afforded by KIR B/x donors was not observed in HLA-mismatched transplantations and was not specific to any particular KIR-B gene. Selecting 10/10 HLA–matched and KIR B/x donors should benefit patients with NHL receiving URD allogeneic transplantation.

Original languageEnglish (US)
Pages (from-to)1602-1607
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Issue number9
StatePublished - Sep 1 2016

Bibliographical note

Publisher Copyright:
© 2016 American Society for Blood and Marrow Transplantation


  • Allogeneic transplantation
  • Genotype
  • Killer immunoglobulin-like receptor
  • Natural killer (NK) cells
  • Non-Hodgkin lymphoma


Dive into the research topics of 'Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation'. Together they form a unique fingerprint.

Cite this